Month: August 2021

Figure 1Fenelon Gold, Tabasco-Cayenne-Gabbro Zones Long SectionFigure 2Fenelon Gold, Plan ViewFigure 3Fenelon Gold, Cross Section 9975_ETORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM) (“Wallbridge” or the “Company”) is pleased to announce that its resource definition drill program for the upcoming maiden mineral resource estimate (“MMRE”) on the Fenelon Gold Property (“Fenelon” or the “Property”) is now almost complete. Drilling has been focusing on multiple areas, within the approximately 1.0 km by 1.2 km central portion of the Fenelon Gold System, to better define the gold mineralization in support of the MMRE. Approximately 260,000 m drilled by the Company at Fenelon within the three years since the commencement of systematic, continuous...

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide (Metablok) is ongoing and will be disclosed to the public following third-party, scientific peer review. After the recruitment of the last patient into the trial in early May, the Company’s Phase II data team reconciled the patient data collected from the seven clinical sites that participated in the trial. The database containing the trial data was then locked at the end of June, which enabled the start of data analysis in late July. All of the Phase II clinical sites in Canada, the U.S....

Conference Call Scheduled for Friday, August 13, 2021 at 9:00 AM ET PORTLAND, Maine, Aug. 05, 2021 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2021 after the market closes on Thursday, August 12, 2021. The Company has scheduled a conference call the next morning, Friday, August 13, 2021, at 9:00 AM ET to review the financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available for seven...

IRVINE, CA, Aug. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Vita Mobile Systems, Inc. (OTC PINK: VMSI), a technology company focused on digital imaging in mobile devices, collection and management of big data and development of artificial intelligence, today announced the acquisition of My2Tum through a share exchange agreement.  My2Tum brings proprietary Artificial Intelligence (AI) technology that allows users to find up-to-date health and safety information by location, complementing VMSI’s own geolocation-based social application platforms. “The significance of this acquisition is immense, and bringing on My2Tum is a huge step forward for VMSI,” stated Sean Guerrero, CEO of Vita Mobile Systems. “The pandemic has made it clear that accurate and timely health and safety information for locations around the world is...

SHANGHAI, China, Aug. 05, 2021 (GLOBE NEWSWIRE) — Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) (“Baozun” or the “Company”), the leading brand e-commerce service partner that helps brands execute their e-commerce strategies in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2021, on Thursday, August 19, 2021, before the open of U.S. markets. The Company will host a conference call to discuss the earnings at 7:30 a.m. Eastern Time on Thursday, August 19, 2021 (7:30 p.m. Beijing time on the same day). Due to the outbreak of COVID-19, operator assisted conference calls are not available at the moment. All participants wishing to attend the call must preregister online before they can receive the dial-in numbers. Preregistration may require a few...

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) — Lexington Realty Trust (“Lexington”) (NYSE:LXP), a real estate investment trust focused on single-tenant industrial real estate investments, today announced results for the second quarter ended June 30, 2021. Second Quarter 2021 HighlightsRecorded Net Income attributable to common shareholders of $71.0 million, or $0.26 per diluted common share. Generated Adjusted Company Funds From Operations available to all equityholders and unitholders – diluted (“Adjusted Company FFO”) of $52.2 million, or $0.18 per diluted common share. Completed 1.1 million square feet of new leases and lease extensions, raising industrial renewal Cash Base Rents by 6.9%. Acquired seven industrial properties for an aggregate cost of $205.5 million. Commenced development of a 1.1 million square foot warehouse/distribution...

        Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancerLibtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death Trial enrolled patients with locally advanced and metastatic disease with squamous or non-squamous histology, and across all PD-L1 expression levels Libtayo has now demonstrated improved overall survival as a monotherapy or in combination with chemotherapy in first-line advanced non-small cell lung cancerPARIS and TARRYTOWN, NY – August 5, 2021 – The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting...

PORTSMOUTH, N.H., Aug. 05, 2021 (GLOBE NEWSWIRE) — Sprague Resources LP (“Sprague”) (NYSE: SRLP) today reported its financial results for the second quarter ended June 30, 2021. Second Quarter 2021 HighlightsNet sales were $657.7 million for the second quarter of 2021, compared to net sales of $358.2 million for the second quarter of 2020. GAAP net loss was $45.6 million for the second quarter of 2021, compared to net loss of $25.1 million for the second quarter of 2020. Adjusted gross margin* was $38.8 million for the second quarter of 2021, compared to adjusted gross margin of $65.2 million for the second quarter of 2020. Adjusted EBITDA* was $3.0 million for the second quarter of 2021, compared to adjusted EBITDA of $28.0 million for the second quarter of 2020.“While second quarter results were weaker than last year’s...

Second-Quarter HighlightsRevenue increased 19.3% on net sales of $99.7 million Gross margin declined 267 basis points to 25.2% Operating income of $10.7 million vs. $10.9 million in the second quarter of 2020 Diluted EPS of $0.58 per shareEVANSVILLE, Ind., Aug. 05, 2021 (GLOBE NEWSWIRE) — Escalade, Incorporated (NASDAQ: ESCA) – today announced its second quarter results for 2021, ended July 10, 2021. The Company posted quarterly revenue of $99.7 million, an increase of 19.3% over prior year, posting another record for its second fiscal quarter. Quarterly diluted earnings per share were $0.58. “Second quarter results reflect strong demand for our products, offset by sharply higher raw material costs, increased wage pressure, and inventory handling costs. Global supply chain issues persist as our logistics team works to keep...

HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responsesA single, intra-tumoral injection of the arenaviral immunotherapeutic resulted in tumor regression in all mice and tumor cures in about 60 percent of recipientsPublication adds to the growing body of evidence supporting the potential of HOOKIPA’s novel arenaviral therapeutics in cancerNEW YORK and VIENNA, Austria, Aug. 05, 2021 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that pre-clinical data on its replicating Lymphocytic choriomeningitis (LCMV) arenaviral-based immunotherapeutic has been published in the peer-reviewed journal, Nature...